Akt

Akt inhibitors target Akt, also called protein kinase B (PKB), a serine/threonine kinase in cell survival signaling. In 1995 the Akt proto-oncogene product was identified as a target of phosphatidylinositol 3-kinase (PI3K) activated by platelet-derived growth factor. Insulin and insulin-like growth factor 1 activate the kinase through phosphorylation at Thr308 and Ser473. The three isoforms, Akt1, Akt2 and Akt3, phosphorylate substrates that control metabolism, proliferation and apoptosis. The category includes the allosteric inhibitor MK-2206 2HCl, the catalytic-site inhibitor capivasertib and the alkylphospholipid perifosine. SC79, by contrast, promotes Akt phosphorylation and serves as an activator in pathway studies.

Items 101-125 of 218

  • Uprosertib hydrochloride
    Cat. No.
    A25626

    Uprosertib hydrochloride

    Synonyms: GSK2141795 hydrochloride

    Uprosertib hydrochloride is a potent and selective pan-Akt inhibitor, characterized by IC50 values of 180 nM for Akt1, 328 nM for Akt2, and 38 nM for Akt3. This compound effectively modulates Akt signaling pathways, which are crucial in regulating cell growth, proliferation, and survival. Uprosertib hydrochloride is widely utilized in cancer research and therapeutic studies to explore potential treatments targeting the Akt pathway.

    25 mg
    $2,285.00
    50 mg
    $2,935.00
    All 3 sizes
  • PX-316
    Cat. No.
    A25634

    PX-316

    PX-316 is a selective Akt inhibitor that demonstrates the ability to phosphorylate Akt while leaving PDK1 and PKC phosphorylation unaffected. Notably, PX-316 also enhances the expression of various mitochondrial-related genes. This compound serves as a valuable tool for investigating pathways involved in colon and breast cancer research.

    25 mg
    $3,295.00
    50 mg
    $4,250.00
    All 3 sizes
  • Erufosine
    Cat. No.
    A25635

    Erufosine

    Synonyms: ErPC3; Erucylphosphohomocholine

    Erufosine is a potent inhibitor of the PI3K/Akt and Ras/Raf/MAPK signaling pathways. It demonstrates significant cytotoxic activity against breast cancer cell lines, specifically MCF-7 and MDA-MB-231, with IC50 values of 40.95 μM and 40.8 μM, respectively. By reducing the phosphorylation levels of PI3K (p85), Akt (PKB), and cRaf, Erufosine serves as a valuable tool in the research of breast cancer and myeloid leukemia.

    Out of stock

    All 3 sizes
  • PI3K/Akt/mTOR-IN-3
    Cat. No.
    A25637

    PI3K/Akt/mTOR-IN-3

    PI3K/Akt/mTOR-IN-3 is a potent inhibitor targeting the PI3K/AKT/mTOR signaling pathway. It demonstrates significant biological activity, exhibiting IC50 values of 0.77 μM, 1.23 μM, and 4.57 μM in MCF-7, HeLa, and HepG2 cells, respectively. Additionally, this compound effectively inhibits the migration of MCF-7 and HeLa cells at a concentration of 4 μM, while also inducing apoptosis and causing cell cycle arrest in the S phase. This makes PI3K/Akt/mTOR-IN-3 a valuable tool for research in cancer biology and therapeutic development.

    25 mg
    $1,275.00
    50 mg
    $1,625.00
    All 3 sizes
  • Akt1-IN-8
    Cat. No.
    A25640

    Akt1-IN-8

    Akt1-IN-8 is a selective inhibitor of AKT1 kinase, demonstrating high potency with an IC50 of 8.8 nM. This compound exhibits significant antiproliferative activity against PC-3 prostate cancer cells, with an IC50 of 3.0 μM. Akt1-IN-8 effectively reduces levels of phosphorylated GSK3β, making it a valuable tool for studying AKT signaling pathways in cancer research and therapeutic development.

    Out of stock

    All 3 sizes
  • WF-10129
    Cat. No.
    A25641

    WF-10129

    WF-10129 is a cytotoxic steroidal compound isolated from the plant Physalis. WF-10129 inhibits liver cancer cell proliferation, induces apoptosis, interferes with metabolism, and significantly reduces lactate production in vitro and in vivo. WF-10129 can also exert anti-tumor activity by regulating the expression of related genes and proteins through the AKT-p53 pathway.

    Out of stock

    All 3 sizes
  • PI3K/AKT-IN-3
    Cat. No.
    A25642

    PI3K/AKT-IN-3

    PI3K/AKT-IN-3 is a selective inhibitor of the PI3K/AKT signaling pathway, known to induce both autophagy and apoptosis in various cell types. This compound is primarily utilized in cancer research to study the effects of PI3K/AKT inhibition on tumor growth and cell survival mechanisms. Its application extends to exploring therapeutic strategies targeting this critical signaling pathway in cancer treatment.

    Out of stock

    All 3 sizes
  • Asperosaponin V
    Cat. No.
    A25644

    Asperosaponin V

    Asperosaponin V is an indirect modulator of key signaling pathways, including PI3K/AKT, BMP-2/p38, and ERK 1/2. This compound stimulates the proliferation of marrow stromal cells and promotes differentiation into osteoblasts, making it valuable for studying bone metabolism. Asperosaponin V holds potential for applications in osteoporosis research and fracture healing studies.

    Out of stock

    All 3 sizes
  • Akt1-IN-6
    Cat. No.
    A25649

    Akt1-IN-6

    Akt1-IN-6 is a potent Akt1 inhibitor with an IC50 of less than 15 nM. This compound selectively targets the Akt1 kinase, disrupting downstream signaling pathways involved in cell survival and metabolism. It is primarily used in research applications focused on cancer biology, metabolism, and other Akt-related pathways. Its high specificity for Akt1 makes it a valuable tool for studying the roles of this kinase in various disease processes.

    25 mg
    $1,780.00
    50 mg
    $2,280.00
    All 3 sizes
  • Anticancer agent 235
    Cat. No.
    A25652

    Anticancer agent 235

    Anticancer agent 235 is a modulator of the PI3K/AKT/mTOR signaling pathway. It promotes reactive oxygen species (ROS) generation and decreases mitochondrial membrane potential, leading to reduced proliferation of cancer cell lines including HCT116, Caco-2, AGS, and SMMC-772 with IC50 values ranging from 0.35 to 26.9 μM. Furthermore, Anticancer agent 235 effectively induces G2/M cell cycle arrest and apoptosis in HCT116 cells, making it a valuable tool for cancer research applications.

    25 mg
    $1,275.00
    50 mg
    $1,625.00
    All 3 sizes
  • 5,4'-Dihydroxy-6,8-dimethoxy-7-O-rhamnosyl flavone
    Cat. No.
    A25654

    5,4'-Dihydroxy-6,8-dimethoxy-7-O-rhamnosyl flavone

    Synonyms: DDR

    5,4'-Dihydroxy-6,8-dimethoxy-7-O-rhamnosyl flavone is a potent Akt inhibitor derived from Indigofera ovata. This compound effectively disrupts the PI3K/AKT and NF-κB signaling pathways, leading to the inhibition of cancer cell invasion and migration. Its biological activity supports research applications in cancer therapeutics and molecular signaling studies.

    Out of stock

    All 3 sizes
  • Akt3 ligand-1
    Cat. No.
    A25655

    Akt3 ligand-1

    Akt3 ligand-1 is a potent inhibitor of Akt3, exhibiting an IC50 of 0.1 nM. This compound serves as a ligand for the development of PROTAC strategies targeting Akt3, facilitating targeted protein degradation. Akt3 ligand-1 is invaluable for research into cancer biology and cellular signaling pathways where Akt3 plays a pivotal role. Additionally, it can be utilized to synthesize PROTAC Akt3 Degrader-1, enabling further exploration of therapeutic potentials in oncological studies.

    Out of stock

    All 3 sizes
  • Akt1-IN-7
    Cat. No.
    A25658

    Akt1-IN-7

    Akt1-IN-7 is a potent Akt1 inhibitor with an IC50 value of less than 15 nM. It effectively hinders the activity of Akt1, a key player in cell survival and growth signaling pathways. This compound is utilized in research focused on cancer biology, metabolic disorders, and other conditions where Akt1 signaling is implicated. Its selective inhibition of Akt1 makes it a valuable tool for elucidating the role of this kinase in various biological processes.

    25 mg
    $1,495.00
    50 mg
    $1,975.00
    All 3 sizes
  • Monomethyl lithospermate
    Cat. No.
    A25659

    Monomethyl lithospermate

    Synonyms: Lithospermic acid monomethyl ester

    Monomethyl lithospermate serves as a PI3K/AKT pathway activator, which is crucial for neuroprotection following nerve injury. This compound enhances the viability of SH-SY5Y neuroblastoma cells by preserving mitochondrial membrane potential and inhibiting apoptosis. Additionally, monomethyl lithospermate reduces oxidative stress in brain tissue of rats subjected to middle cerebral artery occlusion, demonstrating efficacy in mitigating nerve damage associated with ischemic stroke.

    1 mg
    $285.00
    5 mg
    $720.00
    All 2 sizes
  • Monosialoganglioside GM3 (bovine)
    Cat. No.
    A25660

    Monosialoganglioside GM3 (bovine)

    Monosialoganglioside GM3 (bovine) is a ganglioside that functions as an Akt inhibitor, impacting both VEGFR2 and Akt signaling pathways. At a concentration of 20 μM, it effectively inhibits angiogenesis and decreases the proliferation and migration of human umbilical vein endothelial cells (HUVECs). Additionally, it protects against ferroptosis, which is relevant in the context of abdominal aortic aneurysm formation, and impairs insulin signaling by disrupting the insulin receptor-Caveolin-1 complex, contributing to insulin resistance in adipocytes. This reagent is applicable in cancer and metabolic disease research.

    1 mg
    $550.00
    5 mg
    $1,695.00
    All 2 sizes
  • Akt1-IN-4
    Cat. No.
    A25666

    Akt1-IN-4

    Akt1-IN-4 is a selective inhibitor of the AKT1-E17K mutant with an IC50 value of less than 15 nM. This compound effectively disrupts the activity of the AKT signaling pathway, which is implicated in various cancers. Akt1-IN-4 is suitable for research applications focused on studying the role of AKT1 mutations in tumorigenesis and therapeutic resistance.

    25 mg
    $1,405.00
    50 mg
    $1,790.00
    All 3 sizes
  • Puquitinib
    Cat. No.
    A25667

    Puquitinib

    Synonyms: XC-302 free base

    Puquitinib is a selective Akt inhibitor that effectively disrupts the PI3K/AKT/mTOR signaling pathway, promoting autophagy in nasopharyngeal carcinoma cells. This compound demonstrates a dose-dependent antiproliferative effect on CNE-2 cells, which is accompanied by increased autophagosome and autolysosome formation as confirmed by fluorescence and electron microscopy. Puquitinib enhances the conversion of LC3-I to LC3-II and elevates beclin 1 levels while decreasing p62 expression. Additionally, it induces apoptosis in CNE-2 cells, highlighting the interplay between autophagy and apoptosis in mediating cell death processes relevant to cancer research.

    25 mg
    $1,275.00
    50 mg
    $1,625.00
    All 3 sizes
  • TAT-TCL1-Akt-in
    Cat. No.
    A25669

    TAT-TCL1-Akt-in

    TAT-TCL1-Akt-in is an Akt inhibitor that selectively modulates the Akt signaling pathway, which is crucial for cell proliferation and survival. By inhibiting Akt activity, this compound can effectively impact various cellular processes linked to tumorigenesis and cancer progression. TAT-TCL1-Akt-in is useful for research applications focused on cancer biology, signaling pathways, and therapeutic interventions targeting the Akt pathway.

    Out of stock

    All 3 sizes
  • BI-69A11
    Cat. No.
    A25672

    BI-69A11

    BI-69A11 is a selective AKT inhibitor that effectively suppresses the phosphorylation of AKT, disrupting the signaling pathways associated with cell survival and proliferation. This compound demonstrates significant anticancer activity, promoting apoptosis in melanoma and prostate tumor cells. It serves as a valuable tool for research in cancer biology and therapeutic development targeting the AKT pathway.

    1 mg
    $20.00
    2 mg
    $25.00
    All 6 sizes
  • Royleanone
    Cat. No.
    A25676

    Royleanone

    Synonyms: NSC 122417

    Royleanone, a diterpenoid isolated from plants, inhibits the proliferation of cancer cells by inducing cell cycle arrest and mitochondria-mediated apoptosis, also inhibits cell migration potential, inhibits mTOR/PI3/AKT signaling pathway in LNCaP prostate cancer cells.

    5 mg
    $425.00
    All 1 sizes
  • AKT-IN-7
    Cat. No.
    A25679

    AKT-IN-7

    AKT-IN-7 (compound 1-P1) is a potent AKT inhibitor. AKT-IN-7 has the potential for cancer research.

    25 mg
    $1,800.00
    50 mg
    $2,285.00
    All 3 sizes
  • MS5033
    Cat. No.
    A25680

    MS5033

    MS5033 is a potent PROTAC-based degrader targeting AKT (protein kinase B). It demonstrates a DC50 value of 430 nM in PC3 cells, effectively promoting the degradation of AKT. This compound is valuable for studying AKT signaling pathways and evaluating the therapeutic potential of targeted protein degradation in cancer research.

    Out of stock

    All 3 sizes
  • RLX hydrochloride
    Cat. No.
    A25685

    RLX hydrochloride

    Synonyms: PD 139530 hydrochloride

    RLX hydrochloride is a potent inhibitor of the PI3K/Akt/FoxO3a signaling pathway, which plays a critical role in cellular growth and survival. This compound demonstrates significant therapeutic potential in experimental colon cancer by modulating the tumor microenvironment and enhancing the efficacy of cancer immunotherapy. Additionally, RLX hydrochloride can improve the retention of therapeutic agents within tumors when utilized with advanced nanoparticle delivery systems. It may also be effectively combined with other treatment modalities, such as chemotherapy and radiotherapy, to optimize overall cancer therapy outcomes.

    1 mg
    $155.00
    5 mg
    $395.00
    All 7 sizes
  • AKT-IN-9
    Cat. No.
    A25686

    AKT-IN-9

    AKT-IN-9 is a potent inhibitor of AKT (Protein Kinase B), a key regulator of the PI3K/AKT/mTOR signaling pathway. This compound plays a critical role in processes such as cell growth, survival, differentiation, and metabolism. AKT-IN-9 is valuable for research applications focusing on breast and prostate cancer, contributing to a better understanding of tumor biology and potential therapeutic strategies.

    25 mg
    $1,800.00
    50 mg
    $2,285.00
    All 3 sizes
  • Tubulin/AKT1-IN-1
    Cat. No.
    A25687

    Tubulin/AKT1-IN-1

    Tubulin/AKT1-IN-1 is an inhibitor of tubulin polymerization and AKT pathway activation. This compound demonstrates significant inhibition of proliferation and metastasis in H1975 cells, along with a modest induction of apoptosis. Tubulin/AKT1-IN-1 is particularly relevant for research in non-small cell lung cancer (NSCLC), providing a valuable tool for studying therapeutic strategies against this malignancy.

    Out of stock

    All 3 sizes

Items 101-125 of 218

Added to your cart

View Cart Checkout

    Loading...